title: Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
abstract: The prognostic value of interim PET or PET/CT performed after 1-4 cycles of chemotherapy has been widely confirmed in Hodgkin lymphoma and diffuse large B-cell lymphoma but remains unknown in T-cell and natural killer (T/NK) cell lymphomas. Therefore, our aim was to investigate the prognostic value of interim and posttherapy PET/CT in T/NK-cell lymphomas.
  
  
  METHODS
  A retrospective analysis was conducted on data from 88 patients with newly diagnosed T/NK-cell lymphoma who underwent interim (after 1-4 cycles of chemotherapy, n = 62) or posttherapy PET/CT (after the completion of first-line therapy, n = 47). Interim and posttherapy PET/CT status (positive vs. negative) was visually interpreted according to criteria of the International Harmonization Project, and PET/CT status was assessed for its ability to predict progression-free survival (PFS) and overall survival (OS).
  
  
  RESULTS
  Interim PET/CT results were negative in 17 of 62 (27.4%) cases, and posttherapy PET/CT results were negative in 29 of 47 (61.7%) cases. The 2-y PFS and OS rates were 71.9% and 80.2%, respectively, in patients with negative results at interim PET/CT versus 20.5% and 46.9%, respectively, in patients with positive results (P < 0.001 and P = 0.022, respectively). The 2-y PFS and OS rates were 57.8% and 78.0%, respectively, in patients with negative results on posttherapy PET/CT versus 0% and 20.4%, respectively, in patients with positive results (P < 0.001 and P = 0.003, respectively). Bivariate analysis showed that interim PET/CT status and posttherapy PET/CT status remain independent predictors of PFS and OS after controlling for the score on the Prognostic Index for Peripheral T-Cell Lymphoma, Unspecified.
  
  
  CONCLUSIONS
  Both interim PET/CT status and posttherapy PET/CT status are independent predictors of PFS and OS in T/NK-cell lymphomas.
authors: State Key Laboratory of Oncology in South China, Guangzhou, China.
authors: Ya-Jun
authors: YJ
authors: Li
authors: Zhi-Ming
authors: ZM
authors: Li
authors: Xi-Ya
authors: XY
authors: Xia
authors: Hui-Qiang
authors: HQ
authors: Huang
authors: Zhong-Jun
authors: ZJ
authors: Xia
authors: Tong-Yu
authors: TY
authors: Lin
authors: Su
authors: S
authors: Li
authors: Yi
authors: Y
authors: Xia
authors: Xiu-Yu
authors: XY
authors: Cai
authors: Wen-Qi
authors: WQ
authors: Jiang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001692:Biological Transport; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006801:Humans; D007694:Killer Cells, Natural / Q000000981:diagnostic imaging*; D016399:Lymphoma, T-Cell / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D015999:Multivariate Analysis; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019788:Fluorodeoxyglucose F18